← Back to Search

Immunomodulatory Agent

Iberdomide for Kidney Failure

Phase 1
Waitlist Available
Research Sponsored by Celgene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 72 hours following the last dose of iberdomide
Awards & highlights

Study Summary

This study is evaluating whether iberdomide is safe and effective in people with severe renal impairment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 72 hours following the last dose of iberdomide
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 72 hours following the last dose of iberdomide for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Iberdomide Pharmacokinetics - AUC(0-T)
Iberdomide Pharmacokinetics - AUC(INF)
Iberdomide Pharmacokinetics - CLD
+13 more
Secondary outcome measures
Incidence of Adverse Events (AEs)

Trial Design

3Treatment groups
Experimental Treatment
Group I: Group 3: Participants with normal renal functionExperimental Treatment1 Intervention
Normal renal function, as defined by a creatinine clearance (Clcr) > 90 mL/min estimated using the Cockcroft-Gault (C-G) equation, at screening.
Group II: Group 2: Participants with kidney failure who are on intermittent hemodialysis (IHD)Experimental Treatment1 Intervention
Kidney failure participants on intermittent hemodialysis (IHD)
Group III: Group 1: Participants with severe Renal Impairment (RI)Experimental Treatment1 Intervention
Severe Renal Impairment (RI), as defined by an eGFR < 30 mL/min/1.73 m2 and not requiring dialysis, at screening
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CC-220
Not yet FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

CelgeneLead Sponsor
636 Previous Clinical Trials
128,945 Total Patients Enrolled
Alice Wang, MDStudy DirectorCelgene Corporation
1 Previous Clinical Trials
40 Total Patients Enrolled
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,506 Previous Clinical Trials
3,369,504 Total Patients Enrolled
2 Trials studying Kidney Failure
78 Patients Enrolled for Kidney Failure

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this a groundbreaking research endeavor?

"Iberdomide was initially researched in 2016 by Celgene. After a successful study involving 449 patients, the drug achieved Phase 1 & 2 approval. Nowadays, there are 9 trials for Iberdomide hosted across 29 countries and 96 cities worldwide."

Answered by AI

To what demographic is this study available?

"For this trial, 32 volunteers that suffer from kidney impairment must be recruited. The necessary criteria to join the study include a BMI between 18 and 40 kg/m2; body weight above 50kg; an absence of fever (≤38°C or 100.4°F); eGFR < 30 mL/min/1.73 m2 (not needing dialysis); good communication with Investigator along with capacity for comprehension and compliance to restrictions, visits schedule and other protocol requirements including contraception needs."

Answered by AI

Could you provide an overview of the experiments conducted with Iberdomide?

"The initial trials of iberdomide were conducted at Northwest Medical Specialties PLLC in 2016, and 8 clinical studies have since been completed. At present, there are 9 active medical experiments involving this drug; many of them based out of Knoxville, Tennessee."

Answered by AI

Has Iberdomide obtained authorization from the Food and Drug Administration?

"Iberdomide's safety has been investigated to a lesser extent than other drugs and therapies, thus earning it a score of 1. This is due to the fact that this particular trial is in its initial phase, whereby efficacy and safety are yet to be proven conclusively."

Answered by AI

How many participants are actively involved in this clinical experiment?

"Affirmative. Clinicaltrials.gov reveals that this clinical trial, which was initially advertised on 8/12/2021 is still recruiting participants. 32 people are needed to be recruited between 3 different facilities for the study's completion."

Answered by AI

Is recruitment still open for the trial?

"Affirmative. Details hosted on clinicaltrials.gov confirm that this medical research, which was initiated on August 12th 2021, is currently seeking participants. 32 patients need to be enrolled from 3 different healthcare facilities."

Answered by AI

Is the age restriction for this trial limited to individuals below forty years old?

"The cutoff for this clinical trial is 82 years old. For those under 18, there are 6 studies available and 167 options exist for seniors over 65."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function
2021. "Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04933747.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top